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Cílem této diplomové práce je znalost a rozbor metabolického syndromu a jeho 
souvislosti s chorobami kardiovaskulárního systému. V práci budou uvedeny epidemiologické a 
patofyziologické aspekty a komplikace.  
 
V práci budou rozebrány obecně známé farmakologické i nefarmakologické způsoby 
léčby metabolického syndromu. V práci jsou diskutovány i nové terapeutické postupy z hlediska 























The goal of this thesis is the knowledge and analysis of the Metabolic Syndrome and its 
association with the cardiovascular diseases. Aspects such as epidemiology, pathophysiology, 
and complications will be discussed in this thesis.   
The general and known pharmacological and non-pharmacological approaches towards 
the syndrome will be analyzed. It is also discussed in this thesis the new therapeutic approaches 
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 Apo-B – Apolipoprotein type B 
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 VEGF – Vascular Endothelial Growth Factor  
 IGFBP-1 – Insulin like Growth Factor Binding Protein 1 
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 NFE2L2 - Nuclear Factor (Erythroid-Derived 2) - like 2 
 FDKP - Fumaryl Diketopiperazine 
 PEG – Polyethylene Glycol  
 PON1 – Paraxonase 1 
 Lp-PLA2 – Lipoprotein-associated phospholipase A2 
 EMA – European Medical Agency 
 CB1 – Cannabinoid 1  
 IR – Immediate Release 
















Metabolic syndrome is the interconnection of physiological, clinical, biochemical and 
metabolic factors that directly increase risk factors of atherosclerotic cardiovascular diseases, and 
overall increase mortality. (Kaur, 2014) The cluster of certain risk factors; including 
hypertension, hyperglycemia, and dyslipidemia, has been classified as metabolic syndrome. Most 
adults that develop cardiovascular diseases have one or more risk factors. There are six 
components of metabolic syndrome; abdominal obesity, atherogenic dyslipidemia, elevated 
blood pressure, insulin resistance, and/or glucose intolerance, and proinflammatory and 
prothrombic states. The WHO (World Health Organization) clinical criteria for metabolic 
syndrome requires insulin resistance as a diagnosis, along with two other risk factors from high 
blood pressure, elevated triglycerides, low HDL, increased waist circumference or BMI, and 
microalbuminuria. (Beilby, 2004) The WHO definition also mandates that insulin resistance 
must be present for the patient to have metabolic syndrome. Without it, even if all other criteria 
were met, the patient would be considered not to have the disease. Similar to the WHO 
definition, EGIR (European Group for study of Insulin Resistance) defined two additional 
criteria, selected from obesity, hypertension, and dyslipidemia. Obesity has been simplified to 
waist circumference, and microalbuminuria, which was considered a criterion according to 
WHO, was eliminated as a diagnosis. (Huang, 2009) 
According to WHO clinical criteria for metabolic syndrome, it is generally defined as:  
Insulin resistance, one of the following- 
 Type II diabetes 
 Impaired fasting glucose 
 Impaired glucose tolerance 
 
Plus any two of the risk factors-  
 Hypertension (>140 mmHg systolic or >90 mmHg diastolic) 
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 Plasma triglycerides (>1.7 mmol/L) 
 HDL cholesterol (<0.9 mmol/L in men, and <1.0 mmol/L in women) 
 BMI >30 kg/m2  and/or waist/hip ratio >0.9 in men, and >0.85 in women (Beilby, 
2004) 
The presence of metabolic syndrome indicates risk for cardiovascular diseases, as well as 
diabetes mellitus II; however, a greater risk is related to other factors such as age, sex, smoking, 
and gender. Women, for instance, have higher concentration markers (C-reactive protein) in 
comparison with men, possibly due to the increased accumulation of visceral, or/and 
subcutaneous fat. (Kassi et al., 2011) 
II. History of Metabolic Syndrome 
 
Metabolic syndrome was a concept that originated in 1920 by the Swedish physician, Kylin, 
which demonstrated the association of hypertension, hyperglycemia, and gout. Later in 1947, 
Vague found that visceral obesity was associated with metabolic abnormalities, associated with 
type 2 diabetes and cardiovascular disease. In 1965, at the European Association for the Study of 
Diabetes, it was described as a syndrome that comprised hypertension, hyperglycemia, and 
obesity. Following 1988, Reaven described it as “a cluster of risk factors for diabetes and 
cardiovascular disease”, and named it “Syndrome X”. His contribution was introducing insulin 
resistance concept; however, he missed the addition of visceral obesity from the definition. 
Afterwards, in 1922, it was named as “Insulin Resistance Syndrome”. Many groups attempted to 
develop diagnostic criteria for the disease; with the first attempt by WHO in 1998. (Kaur, 2014) 
III. Epidemiology 
 
Metabolic syndrome prevalence is available in ̴ 25% adults worldwide, according to 
International Diabetes Federation (IDF), and increases with advanced age.(Nolan et al., 2017) 
However, this estimate varies widely due to age, ethnicity and gender of the population 
examined. Higher socioeconomic status, higher BMI, sedentary lifestyle, genetic background, 
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diet, smoking, levels of physical activity, family history of diabetes, and education all as well 
contribute to metabolic syndrome. (Kaur, 2014) 
The presence of one diagnosis of metabolic syndrome at a young age increases the risk of 
developing the disease later in life, as well as risk of cardiovascular disease. Therefore, it is 
important to identify the prevalence of metabolic syndrome in the young population (ages 18-
30), not only to prevent risk of cardiovascular diseases, but also to prevent the syndrome by 
targeted interventions. (Nolan et al., 2017) 
 
IV. Pathophysiology of Metabolic Syndrome  
 
Metabolic syndrome is a complex mixture between genetic and environmental factors. 
Understanding the pathophysiology will help identify the people at risk of developing 
cardiovascular diseases, thus helping in early intervention for prevention of the disease. (G and 
P, 2013) 
Criteria for diagnosis of metabolic syndrome have been defined variably by different 
organizations; however, the most accepted criteria were adopted by NCEP (National Cholesterol 


















Metabolic syndrome is also known as “central obesity syndrome”; according to the new 
criteria of IDF (International Diabetes Federation). Central obesity is more metabolically active 
than peripheral fat. Studies have shown that central obesity precedes all the other diagnosis of 
metabolic syndrome; therefore, the best way to prevent it is by weight reduction. Although 
insulin resistance is the major factor for development of metabolic syndrome, central obesity is 
found to be the link between insulin resistance, hypertension and dyslipidemia factors.  
Lipotoxicity is when metabolic products of visceral fats are released directly into the 
portal circulation, which carries the blood moving straight to the liver. Accumulation of free fatty 
acids occur in the pancreas, heart and other organs; leading to organ dysfunction. This produces 
impaired insulin regulation, blood cholesterol, and abnormal heart functions. (G and P, 2013) 
Enlarged and dysfunctional adipose cells are related to the development of visceral fat 
deposits, also known as abdominal adiposity. Proinflammatory biomarkers, such as 
prostaglandins, C-reactive protein, and cytokines such as interleukins (IL-6), tumor necrosis 
factors (TNF-α), and leptin, are secreted by the dysfunctional adipose tissue. With increasing 
obesity, there is a decrease in levels of adiponectin; which is an anti-atherosclerotic adipokine. 
Development of type II diabetes, hyperlipidemia, and cardiovascular diseases are contributed to 
the inflammatory mediators released by adipose tissues. When there is a high proportion of fat to 
muscles, there is a higher contribution to this metabolic dysfunction due to the increase of free 
fatty acids circulation, which requires greater insulin secretion to control glucose metabolism. 
This results in hyperinsulinemia, which desensitizes insulin-sensitive tissues, and therefore, 
makes the individual more susceptible to type II diabetes. The inhibition of insulin receptor 
proteins is also influenced by the decrease of adiponectin secretion. (Paley and Johnson, 2018) 
Computed tomography (CT) or magnetic resonance imaging (MRI) can be used to 
evaluate abdominal obesity, and to measure the amount of visceral fat. CT or MRI can be used to 
evaluate abdominal obesity, and to measure the amount of visceral fat. (G and P, 2013) 
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Guidelines for healthy weight have been based on BMI, and most recently, waist circumference; 
as shown in table 2. (Han and Lean, 2016) 
 










ii. Insulin Resistance (Type II Diabetes Mellitus) 
 
Metabolic syndrome is also known as insulin resistance syndrome, because it is the most 
accepted hypothesis to describe the pathophysiology of the syndrome. Insulin resistance is a 
defect in the insulin action, resulting in hyperinsulinemia. (Aganović and Dušek, 2007) Insulin is 
a dipeptide, containing A and B chains. It is synthesized in the β-cells of the pancreatic islets of 
Langerhans as a precursor, proinsulin. (Wilcox, 2005) It promotes glucose uptake in liver, 
muscles, and adipose cells. Moreover, it can also influence lipolysis, as well as the production of 
glucose by the hepatocytes. (G and P, 2013) Insulin acts in harmony with the growth hormone 
and insulin-like growth factor 1 (IGF -1); growth factor is secreted in response to insulin 
secretion, to prevent insulin induced hypoglycemia. There are other counter regulatory hormones 
that work against the action of insulin to raise blood glucose levels in response to hypoglycemia; 
they include glucagon, glucocorticoids, and catecholamines. They promote glycogenolysis, 
lipolysis, and gluconeogenesis. Secretion of these hormones in excess may contribute to insulin 
resistance. (Wilcox, 2005) 
Overabundance of free fatty acids circulating, released by the adipose tissue mass, is the 
mediator for development of insulin resistance. Free fatty acids decrease the muscle sensitivity to 
insulin by inhibiting insulin-mediated glucose uptake. As the levels of circulating glucose 
increase, insulin secretion from the pancreas also increases, resulting in hyperinsulinemia. In the 
liver, the free fatty acids increase the production of glucose, triglycerides, and very low density 
lipoproteins (VLDL). As a result, the glucose transformation to glycogen is decreased, while the 
lipid accumulation in triglyceride is increased. (Aganović and Dušek, 2007) 
A common condition associated with insulin resistance is type 2 diabetes mellitus; insulin 
resistance predates diabetes development. The defect exists in muscle cells and adipocytes, 
where impaired GLUT-4 results in impaired insulin-mediated glucose transport. Impaired 
glucose tolerance and diabetes develop as the β-cells fail to compensate for the insulin resistance. 
Function of β-cells deteriorates as glucose levels rise, reducing glucose sensitivity and worsening 
hyperglycemia. The islets cells mass is usually reduced in size in diabetic patients. (Wilcox, 
2005) There are several causes for development of severe insulin resistance, which are shown in 





Table 3. Causes of Severe Insulin Resistance. 
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833480/ 
 
iii. Diabetic dyslipidemia 
 
Dyslipidemia is an endocrine and metabolic disorder related to genetic predisposition; 
however, there are other factors, including obesity, diet, and lifestyle that play a role in acquiring 
dyslipidemia. Lipids are compounds that are insoluble in aqueous media; they include 
cholesterol, phospholipids, and triglycerides. Cholesterol and triglycerides are important to the 
body, but due to their insolubility, they should be packed into lipoproteins to facilitate their 
transport. The lipoprotein molecule consists of cholesteryl esters, triglycerides, fatty acids, and 
fat-soluble vitamins. The outer layer of lipoprotein molecule is polarized and helps with lipid 
transport into the blood. There is a hydrophilic layer of apolipoproteins, which are recognized by 
enzymes. Apo B induces the formation of VLDL in the liver. 
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HDL, a lipoprotein considered as “good cholesterol”, collects the abundant glycerol, cholesterol, 
and fatty acids from the blood and returns them back to the liver. This is called reverse 
cholesterol transport, unlike the VLDL activity.  
Dyslipidemia can be classified into;  
 Primary dyslipidemia- caused by monogenic or polygenic mutations. It is usually 
associated with overproduction of lipoproteins, or a decreased clearance from the 
circulation.  
 Secondary dyslipidemia- they are disorders that can be subdivided into different grades of 
severity, with no genetic disorder. 
a) Hypercholesterolemia- associated with hyperthyroidism, obstructive liver 
disease, nephrotic syndrome, and the use of certain drugs; cyclosporine, 
thiazides.  
b) Hypertriglyceridemia- associated with obesity, diabetes mellitus, and the 
use of drugs; beta-blockers, glucocorticoids.  
c) Low HDL- associated with obesity, diabetes mellitus type 2, rheumatoid 
arthritis, and drugs such as beta-blockers. (Devi and Jyothi, 2017) 
Dyslipidemia is also known as increased in free fatty acids flux, increased triglycerides 
levels, low HDL cholesterol levels, increased LDL values, and elevated apolipoprotein B values. 
It is a risk factor for cardiovascular diseases; it has been connected with both myocardial 
infarction and stroke in patients with metabolic syndrome. The increase of the free fatty acids is 
due to the inability to integrate to triglycerides by the adipose tissues; consequently, there is 
reduced fatty acids trapping and retention by the adipocytes. This results in an increased flow of 
the free fatty acids back to the liver. The increased flux of the free fatty acids to the liver 
stimulates triglycerides synthesis from the hepatocytes, which stimulates the secretion of VLDL 
containing triglycerides, and the apo-B synthesis in the liver. 
Adipose tissue has been shown to be an endocrine organ producing adipocytokines, 
including leptin, angiotensin, TNF-α, IL-6, and transforming growth factor β. These proteins are 
all increased in the state of obesity, and can induce diabetes or obesity related insulin resistance. 
(Kolovou and Anagnostopoulou, 2005) 
The dyslipidemia of type 2 diabetes mellitus is associated with high triglycerides levels, 
and low HDL levels, as well as the presence of LDL particles. These factors contribute to the 
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development of atherosclerosis before diagnosis of diabetes mellitus. Usually, in type 1 diabetes 
mellitus, in the presence of hypertriglyceridemia, HDL levels are normal; unless the control of 
glycaemia is poor, or there is a case of nephropathy (Schofield et al., 2016). HDL triggers the 
secretion of insulin from pancreatic β-cells, and enhances glucose uptake from skeletal muscles; 
therefore, low levels of HDL are associated with cardiovascular diseases. In type II diabetes, 
HDL levels become dysfunctional, and therefore, alterations in paraxonase 1 (PONS1) and 
lipoprotein associated phospholipase A2 occur (Femlak et al., 2017). LDL levels are elevated in 
patients with diabetes due to the reduced catabolism of LDL, which leads to a prolonged duration 
of LDL in plasma; promoting lipid deposition in arterial walls (Vergès, 2015). 
In the below figure, Figure 1, the alterations in free fatty acids metabolism is associated with the 
pathophysiology of both hyperglycemia and dyslipidemia (Kirk and Klein, 2009). 
 
 
Figure 1. Physiological interrelationship between fatty acids metabolism, insulin resistance, and 









iv. Arterial Hypertension 
 
Arterial hypertension is an important symptom of metabolic syndrome, with many 
complicated underlying mechanisms to its development. Metabolic syndrome is present in one 
third of patients with hypertension, as it is a classical diagnosis of metabolic syndrome. Visceral 
obesity and insulin resistance are associated with levels of blood pressure. 
Visceral obesity plays a role in the development of hyperglycemia, hyperlipidemia, and 
hypertension. Adipose tissues have been found to secrete adipocytokines, which induce not only 
diabetes and insulin resistance, but also hypertension (Yanai et al., 2008). The renin angiotensin 
system (RAS) is activated in arterial hypertension (Re, 2009). Adipocytes have been found to 
regulate the production of RAS components, angiotensin I and II, where they have localized 
receptors on adipocytes. Angiotensin II has been found to regulate the adipocyte growth and 
differentiation, the lipid metabolism, and the release of adipokines (Cassis et al., 2008).  Given 
that angiotensinogen is synthesized by the adipocytes; thus, increasing the secretion of 
angiotensinogen will consequently lead to an increase in angiotensin I by renin release, and 
secondarily the release of angiotensin II. An increase in sympathetic activity could also lead to 
an increase in renin activity. There is an increase in the renal tubular reabsorption of sodium due 
to the elevated angiotensin II secretion, as well as stimulation in the synthesis of aldosterone, the 
sodium-retaining hormone (Re, 2009). 
 









Being the main pathophysiological feature of metabolic syndrome, insulin resistance is 
connected with hypertension via several mechanisms. Insulin has an anti-natriuretic effect by 
stimulating the renal sodium reabsorption; thus, the anti-natriuretic effect is increased in patients 
with insulin resistance, leading to the development of hypertension in metabolic syndrome.   
Some in-vitro studies show the relation between insulin and endothelin-1 stimulation, as well as 
its action on the vascular walls.  Endothelin-1 is an amino acid causing vasoconstriction; its 
levels increase in the plasma when there are high serum insulin levels. Endothelin-1 receptor 
antagonist has been shown to decrease blood pressure in animals with insulin resistance and 
hypertensive cases; thus, proving the significance of endothelin-1 in hypertension pathogenesis.  
An increase in inflammatory mediators has also shown to be linked with hypertension. TNF-α is 
linked to the pathophysiology of hypertension by stimulating the production of endothelin-1 and 
angiotensinogen. Serum TNF-α is shown to be related with systolic blood pressure, and 
monocyte secretion of TNF-α has been seen from hypertensive patients.  
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Interleukin-6 (IL-6), a cytokine which mediates inflammatory responses, stimulates the 
sympathetic nervous system, which results in hypertension. Moreover, IL-6 administration leads 
to increased heart rate and norepinephrine levels. Furthermore, IL-6 has also shown to increase 
angiotensinogen and angiotensin II plasma levels; which all lead to the development 
hypertension. (Yanai et al., 2008)  
V. Clinical complications of Metabolic Syndrome 
 
Metabolic syndrome can lead to a number of complications; these include atherosclerosis, 
along with other cardiovascular disorders, neuropathy, arthritis, cognitive impairment, and 
colorectal cancer. (Nerkar et al. 2015) 
Systemic inflammation is the link between metabolic syndrome and atherosclerosis. Central 
obesity in patients with metabolic syndrome and atherosclerosis has been associated with 
systemic inflammation, overproduction of reactive oxygen species (ROS), TNF-α, and IL-6. 
Central obesity is also connected with atherosclerosis by both insulin resistance, and 
dysregulation of adipocytokine production. The disturbance of adipocytokine occurs due to the 
methylation of different genes, including IL-6, TNF-α, GLUT-4; which are responsible for 
inflammation and oxidative stress. Insulin resistance is affected by the proinflammatory 
outcomes, which leads to microvascular and macrovascular alterations; influencing the 
progression of atherosclerosis. In hyperlipidemia, cholesterol concentrates in macrophages; 
leading to an inflammatory response.  (Fg et al., 2017) Complement component 1 (C1q) is a 
protein that plays a dual role in atherosclerosis. Activation of the complement causes 
inflammation, as well as promoting disease progression. However, in the early stages of the 
disease, it acts as an atheroprotective. (Ho et al., 2016)  It increases anti-inflammatory cytokines 
and decreases proinflammatory cytokines; reducing disease markers such as cholesterol and 
triglycerides. (Fg et al., 2017) 
Neuropathy is a common condition of metabolic syndrome, with significant morbidity 
especially in the elderly. Hyperglycemia, a component of metabolic syndrome, has been 
associated with neuropathy. Thus, treating hyperglycemia has been shown to decrease 
neuropathy in patients with type I diabetes mellitus. However, in patients with type II diabetes, 
controlling glucose has an insignificant effect in treating neuropathy, proving other factors that 
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might be causing nerve injury in these patients. Other mechanisms of nerve injury include fat 
deposition in nerves, extracellular protein glycation, mitochondrial dysfunction, and oxidative 
stress. (Callaghan and Feldman, 2013) Metabolic syndrome associated hyperglycemia and 
hyperlipidemia cause cellular damage by reactive oxygen species (ROS) production, which cause 
mitochondrial dysfunction, as well as endoplasmic reticulum stress; these lead to direct neuronal 
damage. (Nerkar et al., 2015) 
Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with pain, 
deformity of joints, as well as systemic inflammatory response in lungs, heart, and kidneys. (Lee 
et al., 2016) It could be caused by a variety of genetics and lifestyle choices, such as smoking. 
Patients with rheumatoid arthritis are prone to atherosclerosis as well as its complications. 
Cardiovascular diseases, as well as myocardial infarction, have been shown frequency in 
rheumatoid arthritis patients, with chronic inflammation, specifically autoimmune systemic 
inflammatory response, as a major contributor to both metabolic syndrome and atherosclerosis. 
Metabolic syndrome has been shown to occur in up to 45% of rheumatoid arthritis patients. 
Patients with RA are more likely to have low levels of HDL cholesterol, high levels of 
triglycerides, and increased levels of inflammatory markers such as C-reactive protein (CRP). 
Proinflammatory cytokines, such as TNF-α and IL-1 are produced by the immune cells activated 
in the atherosclerotic plaque; inducing the production of IL-6, CRP, fibrinogen, and serum 
amyloid A. Chronic inflammation of  CRP leads to uncontrollable inflammation, causing 
increase risk of cardiovascular diseases. (Cojocaru et al., 2012) The proinflammatory cytokines 
are secreted into the systemic circulation, and increase the risk of insulin resistance by acting on 
adipose tissues, skeletal muscles, and the liver. (Lee et al., 2016) 
Metabolic syndrome has also been associated with cognitive dysfunction; having a 
negative impact on cognition. Medical factors such as type II diabetes mellitus, cardiovascular 
diseases, silent brain lesions, and MRI findings have been controlled; and metabolic syndrome 
has been found to be linked to memory deficits, processing speed, and overall intellectual 
functioning. Potential explanatory factors for metabolic syndrome effect on the brain may 
include neuroinflammation, oxidative stress, abnormal brain lipid metabolism, and impaired 
vascular reactivity. Impaired cerebrovascular reactivity and increased carotid stiffness has been 
reported in adults suffering from metabolic syndrome. The carotid artery is the main blood 
supply to the central nervous system; thus, the carotid atherosclerosis has been linked to 
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cognitive impairment as well as brain atrophy. Endothelial dysfunction as well as carotid 
stiffness has been found in children and adult patients of not only metabolic syndrome, but also 
patients with obesity, hypertension, and type II diabetes mellitus; especially in patients with 
uncontrolled type II diabetes mellitus, where they suffer from more carotid alterations. (Yates et 
al., 2012) Other studies have found that vascular risk factors, including glucose intolerance, 
insulin resistance, central obesity, lipid abnormalities, and hypertension play a role in the 
pathogenesis of dementia and Alzheimer’s disease. Cholesterol, being a main component of 
myelin and cell membrane, maintains the function of cerebral tissues. Cholesterol disorder 
decreases the membrane fluidity of the hippocampus, a memory center in Alzheimer dementia. 
Beta amyloids destroy cerebral tissues cell structure; and cholesterol has been found to reduce 
beta amyloid formation in the hippocampus neurons, therefore, delaying Alzheimer’s onset. 
Hypertriglyceridemia causes arteriosclerosis by increasing the viscosity of the blood and 
lowering cognitive functions. Hypertension has also been found to cause cerebrovascular 
diseases and cerebral infarction. It also decreases nicotinic receptors sensitivity to acetylcholine. 
Chronic high blood sugar level inhibits the secretion of cerebral acetylcholine, and causes loss of 
neurons, leading to decrease in cognitive functions. (Oh et al., 2011) 
Colorectal cancer accounts for 13% of new cancer cases in Europe, and it is the mostly 
diagnosed cancer. (Trabulo et al., 2015) Studies have shown a link between hyperinsulinemia 
and colorectal cancer risk. Adipocytes, in obesity, play a role in colorectal cancer pathogenesis. 
Adiponectin, a protein hormone secreted by adipocytes, regulates glucose metabolism and 
breakdown of fatty acids, as well as sensitizing peripheral tissue to insulin. There is a decrease in 
plasma adiponectin concentrations as visceral fat accumulates. Adiponectin also inhibits the 
macrophages secretion of TNF-α, and therefore, stimulate angiogenesis by the destructive action 
on endothelial cells. As adiponectin levels in plasma decrease, tumorigenesis mediated by TNF-α 
is triggered. Insulin and insulin-like growth factor 1 (IGF-1) trigger mitogenesis and inhibit 
apoptosis in endothelial cells; leading to tumorigenesis. Increased secretion of vascular 
endothelial growth factor (VEGF) from the IGF-1 leads to angiogenesis, which plays a role in 
tumor growth and metastasis. Moreover, insulin inhibits insulin-like growth factor binding 
protein 1 (IGFBP-1) transcription, which increases IGFs in plasma. The high levels of IGFs in 
the circulation lead to increased cell proliferation and inhibition of apoptosis; which causes 
colorectal cancer formation. Therefore, in metabolic syndrome, insulin, IGF-1, and adiponectin 
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have tumorigenic actions; as well as adiponectin inhibition effect on TNF-α level, which all 
contribute to an increased risk of colorectal cancer. (Nerkar et al., 2015) 
VI. General therapy of Metabolic Syndrome  
 
Metabolic syndrome is a chronic, inflammatory state with serious systemic side effects; 
therefore, identification and management of patients is important to reduce the risk of 
development of diseases. There are effective preventative non-pharmacological approaches that 
include lifestyle changes, weight loss, diet, and exercise.  
There are some therapies for weight loss; including calories restriction, increased physical 
exercise, and in the appropriate patients, weight reducing drugs can be given. It is recommended 
a goal for weight loss with a 10% reduction in the first six months, and then a continued weight 
loss until BMI less than 25 is reached. Minor weight loss of 5-10% could influence blood 
pressure, blood glucose and insulin levels, and triglycerides levels, as well as increase HDL 
levels. Regular exercise has shown an effect on abdominal fat weight loss, and to prevent regain 
of the weight lost. (Kaur, 2014) Studies have shown that exercise and physical activity has an 
effect in preventing atherosclerotic mortality and morbidity. There are some mechanisms that 
play a role in the protective effect of physical activity; they may be related to the direct action of 
physical activity on the heart by increasing myocardial oxygen supply, as well as improving 
myocardial contraction and electrical stability of the heart.  
Diet changes has many beneficial effects; carbohydrate consumption has an effect on weight 
gain, diabetes mellitus type II, and obesity and therefore, it is important to recognize the 
problems that can occur due to the wrong intake of carbohydrates, such as simple sugars, while 
emphasizing the importance of including the right complex carbohydrates, such as potatoes and 
bread, into the diet. Fats, including oils, fats and waxes, comprise 30% of daily energy intake; 
however, it is important to clarify the saturated fats promote dyslipidemia and atherogenesis, and 
therefore, the required fat intake should consist of unsaturated oils, such as vegetable oils, which 
prevent serious disorders such as atherogenesis and hypertension. In the following figure, Figure 
3, the role of non-pharmacological approach to metabolic syndrome is explained briefly. 









Weight reducing drugs are recommended for patients with BMI of at least 30, along with 
other comorbidities that influence their weight gain. These pharmacological groups of drugs 
include two classes; appetite suppressants, and inhibitors of nutrients absorption. Phentermine 
derivatives, such as Fenfluramine and sibutramine are some appetite suppressants. They are 
taken in the morning to suppress the appetite for the afternoon and evening. Studies have shown 
that sibutramine induced weight loss has led to reductions in the risk factors associated with 
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metabolic syndrome. The treatment with such drugs has an effect on the visceral fat by reducing 
it, improves the lipid levels, and affects glycosylated hemoglobin and uric acid by decreasing 
their concentration. Another class of drugs is the inhibitor of nutrient absorption, Orlistat. It 
works by preventing the absorption of up to 30% of the fat consumed; therefore, it should be 
taken at the time of consumption. However, it comes along with side effects that may include 
flatulence and oily leakage into the stool.  
Generally, the side effects caused by these anti-obesity drugs are unpleasant, which may 
lead to non-compliance and low tolerance, especially in long term usages (Kaur, 2014).  
Phentermine has sympathomimetic actions similar to amphetamine, is approved by the FDA only 
for the short-term use due to its adverse effects that include dry mouth, insomnia, palpitations, 
and increased blood pressure. Fenfluramine and its isomer dexfenfluramine, the serotonergic 
drugs that suppress the appetite, have been withdrawn by the FDA in 1997 due to heart valve 
damage in women taking the therapy. Sibutramine was approved in 1997; however, it showed 
adverse effects such as headache, dry mouth, insomnia, and constipation. It has also been found 
to increase heart rate and blood pressure. In long term treatment, Sibutramine also increased the 
risk of non-fatal myocardial infarction as well as stroke; and therefore, it has been withdrawn by 
the FDA in 2010. Rimonabant, a suppressor of the endocannabinoid system blocks the 
cannabinoid type 1 receptor (CB1), which induces anorexigenic and thermogenic effects. It was 
approved by EMA in 2006; however, psychiatric adverse effects such as anxiety, depression and 
suicidal attempts have occurred, and therefore, the suspension of Rimonabant by EMA has been 
recommended in 2008. It has never been approved by the FDA as well.  Orlistat has common 
side effects such as flatulence, diarrhea, bloating, and abdominal pain. It also interferes with the 
absorption of the fat-soluble vitamin (A, D, E, K). Orlistat was approved without a conduction of 
long-term trial on safety. The FDA has been notified of certain liver injuries reported; however, 
the FDA regarded the risk as low, and allowed the continuation of Orlistat (Cheung et al., 2013). 
Pharmacological approaches are usually considered when the risk factors are not reduced with 
the preventative measures and other non-pharmacological approaches (Kaur, 2014). First line 
pharmacological therapy for cardiovascular heart diseases influencing metabolic syndrome 





i. Hypolipidemic Treatment 
 
The primary goal in hypolipidemic treatment is reducing the LDL cholesterol levels; 
however, if triglycerides level is higher than 28 mmol/L (500 mg dL), then lowering TG levels 
takes priority over LDL lowering. After both levels are maintained, increasing HDL cholesterol 
levels is the next target. HDL levels are increased by weight loss and physical activity.  
a. Statins 
 
One of the main recommended drugs for LDL lowering are statins, also known as 
hydroxymethyl glutaryl coenzyme A reductase inhibitors. HMG-CoA reductase is the key 
enzyme in the cholesterol synthesis that helps in the conversion of HMG-CoA to Mevalonate; 
which is an early step in cholesterol biosynthesis. Therefore, inhibition of HMG-CoA reductase 
by statins lowers the cholesterol levels in the blood, as well as lipoproteins containing Apo-B in 
hypercholesterolemic patients. Statins influence the secretion of both LDL and VLDL levels in 
hyperlipidemic patients, as well as decreasing triglycerides levels by inhibiting intracellular 
cholesterol biosynthesis. Atorvastatin has been shown to decrease LDL levels, as well as 
improve hepatic lipoprotein production. Simvastatin, another member of the statins, has been 
shown to decrease LDL levels, and raise HDL plasma concentration in the long term (Binesh 
Marvasti and Adeli, 2010). In hypercholesterolemia, HDL was found to be raised approximately 
4-10%. Although the changes in levels are not dose-related, the increase in HDL was found to be 
proportional to the reduction in Apo-B lipoproteins (McTaggart and Jones, 2008). Simvastatin 
and Rosuvastatin were found to increase HDL concentrations compared to Atorvastatin; 
however, the HDL increase was independent of the LDL decrease effects of statins (Barter et al., 
2010). Rosuvastatin is a new statin member with high efficacy in reducing LDL levels compared 
to other statins, due to its high binding ability to HMG-CoA reductase. This high binding of 
Rosuvastatin causes a stronger inhibition of the enzyme, which leads to a higher therapeutic 
effect. Rosuvastatin also has a longer half-life compared to the other statins, with a higher 
selectivity for hepatic cells; as they are the main site of cholesterol synthesis. Statins are also 
used in primary and secondary prevention of other cardiovascular diseases. (Binesh Marvasti and 
Adeli, 2010) Rhabdomyolysis is the most serious adverse effect occurring from the use of 
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statins; however, it occurs very rarely (about 0.1% or less). Other adverse effects may include 
derangement in liver functions, and diabetogenic potential. They also interact with drugs with 
have an influence on cytochrome P450 group. Therefore, statins are considered a safe group for 
therapy for most patients; however, patients with co-morbidities, polypharmacy, or alcohol abuse 
are at an increased risk of severe side effects from the long-term use of statins. (Ramkumar et al., 
2016)  
b. Cholesterol Absorption Inhibitors 
 
Another group of hypolipidemic agents are cholesterol absorption inhibitors; which are a 
class of drugs that decrease the absorption of cholesterol from the small intestine, and therefore 
decrease the cholesterol reaching the liver; which allows more cholesterol to be removed from 
the blood. (Binesh Marvasti and Adeli, 2010) Cholesterol absorption inhibitor, Ezetimibe, targets 
the uptake at the jejunum enterocytes. It primarily targets the Nieman Pick C1 like 1 transport 
protein. However, Ezetimibe has not shown to have an effect on triglycerides or fat-soluble 
vitamins. It is metabolized through glucoronidation in the liver, then it is excreted into the bile 
back to the intestinal lumen, finally, it is excreted into the feces. Because Ezetimibe undergoes 
enterohepatic circulation, it has a long half-life of 22 hours. Ezetimibe is not metabolized by 
Cytochrome P450, and therefore, does not interact with other medications such as statins, 
fibrates, amiodarone, or amlodipine. (Phan et al., 2012)  At a given dose of 10 mg/day, studies 
have shown a reduction in LDL cholesterol levels by 20-25%; either by monotherapy of 
Ezetimibe, or in combination with statins. It is advised to use when a statin is insufficient to 
reach LDL level of 5 mmol/L (100 mg/dL), Ezetimibe should be added to the therapy alongside 
the statin. Ezetimibe, however, was not shown to have similar effects as statins on atherosclerotic 
risk factors; such as anti-inflammatory, antioxidant, and effects on nitric oxide bioavailability, 
yet it is still prescribed alongside Statins, in the treatment of hypercholesterolemia. (Binesh 






c. Fibrates  
 
Fibrates are another type of hypolipidemics for reduction of triglycerides, VLDL, as well 
as increasing HDL. They bind and activate Peroxisome Proliferator-Activated Receptor α 
(PPARα), regulating gene expression, and therefore influencing the metabolism of fatty acids 
and lipoproteins in the liver, muscles, and kidneys. (Shipman et al., 2016) The activation of 
PPARα leads to increased lipolysis, as well as increased plasma clearance of atherogenic 
triglyceride lipoproteins. The activation, as well, increases synthesis of ApoAI and ApoAII, 
which are major proteins in HDL. Treatment with gemfibrozil leads to an increase in LDL size, 
and decrease in LDL by 5%, while increasing HDL by 10%; similarly, treatment with 
finofibrate, ciprofibrate, and bezafibrate have shown equal effects on LDL levels.  
There are common side effects associated with fibrates therapy; including gastrointestinal 
adverse effects, flatulence, nausea, diarrhea, constipation, dermatological effects such as pruritus, 
and urticaria. Musculoskeletal adverse effects such as pain and cramps, as well as neurological 
effects such as headache and dizziness, are less common.  (Goldenberg et al., 2008) Adjusting 
the dose is recommended in renal insufficiency, and they are contraindicated in liver and 
gallbladder diseases. If fibrates are used alongside statins, Fenofibrate is the recommended 
fibrate to use, as gemfibrozil has a higher risk of myositis. Fenofibrate binds to proteins and may 
interact with Warfarin, and therefore, levels should be closely monitored.  
d. Omega-3 Fatty Acids 
 
Omega-3 fatty acids are also FDA approved for treatment of severe hypertriglyceridemia, greater 
than 1000 mg/dL, and LDL levels are lowered by 20%-50%. The triglyceride lowering is usually 
dose related in the case of omega-3 fatty acids supplements, with a required dose of 3-4 grams 









Niacin is also used in the treatment of lipid and lipoprotein abnormalities.  It reduces 
triglycerides by 15%-40%, by reducing triglyceride synthesis. (Karanchi and Wyne, 2019) 
Several adverse effects have been reported with the use of Niacin; these include, nausea and 
vomiting, flushing, epigastric burning, and jaundice. (RIVIN, 1962) Flushing was found to be 
reduced by using aspirin and starting with a low dose. Crystalline, immediate-release (IR) niacin 
is absorbed rapidly by the body, reaching peak levels in 30-60 minutes, causing immediate 
flushing to the patients. Sustained-release niacin formulations are new formulations intended to 
reduce the flushing, due to the delay niacin absorption during treatment. However, sustained-
release niacin has been found to cause hepatotoxicity. Another newer extended-release niacin 
formulation has shown to reduce flushing side effects. It could also be safely combined with 
statins to lower LDL and TGs, with no risk of flushing as a side effect (Kamanna et al., 2009).  
Niacin is also contraindicated in patients with peptic ulcer. (Karanchi and Wyne, 2019) 
ii. Hypertension Treatment 
 
Hypertension occurs when systolic blood pressure is ≥140 mmHg and diastolic blood 
pressure is ≥90 mmHg. It is considered a strong risk factor for major cardiovascular diseases, 
and usually it is asymptomatic, which increases exposure time to the disease, leading to more 
cardiovascular complications. Hypertensive therapy reduces the complications of cardiovascular 
diseases such as heart attack, stroke, and heart failure (Freeman et al., 2017). 
a. ACE Inhibitors 
 
The renin-angiotensin system (RAS) is known for regulation of cardiovascular functions, 
as well as hydromineral balance. Overactivity of the RAS has been found in obese patients, as 
well as in hypertensive patients. Therefore, drugs that have an effect on Angiotensin II synthesis- 
also known as angiotensin converting enzyme inhibitors, or angiotensin II receptor blockers- 
have shown to be effective in treatment of hypertension. After synthesis of Angiotensin-II, it 
either binds to receptors in the target areas, such as muscles, kidneys, adrenal cortex, and brain, 
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or it is degraded to yield further products, such as Angiotensin III and Angiotensin IV, which 
have an effect on memory and learning  (de Kloet et al., 2010). 
In the below figure, Figure 4, the renin-angiotensin system pathway is explained (Perlot and 
Penninger, 2013).  
 
Figure 4. The classical renin-angiotensin system.  
Source: https://www.sciencedirect.com/science/article/pii/S128645791300155X 
Common generic names for ACE inhibitors are Captopril, Perindopril, Ramipril, 
Enalapril, and Lisinopril, and for ARBs –also known as sartans – are Candesartan, Valsartan, 
Telmisartan, and Losartan. ([Table], Common Generic and Brand Names for ACE Inhibitors and 
ARBs, 2010) 
All the ACE inhibitors are administered per oral, except for Enalapril, which is given 
intravenously. In patients with heart failure, salt-depleted patients, and renal impaired patients, 
the dose should be decreased. Almost all the ACE inhibitors are prodrugs, which are activated in 
the body after ingestion, except Lisinopril and Captopril, which are not prodrugs, and do not 
require activation. The activation of the prodrugs usually occurs in the liver, therefore, when a 
patient has hepatic insufficiency, a non-prodrug ACE inhibitor is recommended to prescribe.  
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Adverse effects may occur in patients on ACE inhibitors therapy, they may include dry 
cough – in which the patient decides if they can tolerate it – since there is no treatment for the 
cough. 
Another significant adverse effect to occur is angioedema; it can occur anywhere in the 
body including the tongue, glottis and larynx, which may compromise the patient’s ability to 
breathe, due to the airway obstruction. In this case, diphenhydramine or methylprednisolone may 
be used until the edema effect subsides.  
Renal failure has also been reported in patients taking ACE inhibitors; patients with 
already renal insufficiency are susceptible to worsening of their renal function, and therefore, 
constant renal function monitoring is required.  
Another common adverse effect to any hypertensive medication is hypotension. Patients 
at risk of hypotension are patients with heart failure, ischemic heart disease, hyponatremia, and 
renal dialysis.  
Hypokalemia is another common adverse effect that occurs due to the use of ACE 
inhibitors; patients at risk are patients with renal insufficiency, as well as potassium-sparing 
diuretics users. Usually the treatment should depend on the level of potassium, and on the kidney 
functions.  
ACE inhibitors are contraindicated in patients with history of angioedema or previous 
hypersensitivity related to ACE inhibitors. They should as well not be given in pregnancy, as 
they may cause deformities. (Herman and Bashir, 2019) 
b. β-blockers  
 
β- Blockers have been used in hypertension for many years. Studies have shown that the 
use of β-blockers reduced cardiovascular mortality, and they are recommended as first line and 
second line antihypertensives.  
Propranolol, a first generation β-blocker, blocks both β1- and β2 – receptors. By blocking 
β1- receptors, there is an inhibitory effect on myocardial contractions, causing a negative 
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chronotropic, dromotropic and inotropic effect. By blocking β2-receptors, there is a contraction 
of smooth muscles, causing bronchospasm. Second generation blockers, such as Atenolol, 
Metoprolol, and others, have high β1-receptor sensitivity, and are usually preferred in patients 
with chronic lung diseases, as well as smokers. Furthermore, Carvedilol, a third-generation agent 
has additional vasodilatory properties due to the α-adrenergic blockage.  
The half-life of β-blockers varies from 9 minutes, such as Esmolol, to 24 hours, such as 
Nadolol and Penbutolol. Longer half-life drugs lead to longer action, which increases medication 
adherence; and therefore they are more preferred in hypertension. (Stafylas and Sarafidis, 2008) 
Common adverse effects of β-blockers, specifically cardio-selective β-blockers include 
bradycardia, hypotension, lower exercise potential, and atrioventricular nodal block. There are 
other side effects that include nausea, vomiting, dizziness, headache, discomfort, fatigue, and dry 
mouth. There is a risk of β1-blockers administration in diabetic patients due to their ability to 
mask hypoglycemia induced tachycardia, which is a warning symptom for patients suffering 
from hypoglycemia. β- Blockers also interact with several drugs causing adverse effects; these 
drugs include nitrates, ACE inhibitors, and other hypertensive drugs.  
β1 blockers are usually contraindicated in patients with chronic obstructive pulmonary 
disease and asthma. They also should not be administered to patients with fluid retention, as well 
as patients with heart block. (Tucker and Theetha Kariyanna, 2019) 
c. Calcium Channel Blockers 
 
Calcium channel blockers, another type of antihypertensives, inhibit the L-gated calcium 
channels, and also cause vasodilation; they are being used as first and second line therapy. 
Calcium channel blockers are categorized into 3 categories according to their chemical 
structures; benzothiazepines (Diltiazem), phenylalkylamines (Verapamil), and dihydropyridines 
(Nifedipine, Felodipine, Amlodipine, and others). They bind to the α1 subunit, inhibiting cell 
excitability, and blocking calcium influx. They also have negative inotropic and chronotropic 
effects. (Ozawa et al., 2006) 
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Adverse effects may occur with calcium channel blockers usage. Constipation and 
bradycardia are common with Diltiazem and Verapamil, while dihydropyridines may cause 
lightheadedness, peripheral edema, and headache. Diltiazem and Verapamil are therefore 
contraindicated in patients with heart failure, because of the possibility of bradycardia and 
worsening cardiac output. (McKeever and Hamilton, 2019) 
d. Diuretics 
 
Diuretics are another class of anti-hypertensives that have been used mainly for primary, 
uncomplicated hypertension, as well as controlling edema. Diuretics reduce sodium reabsorption 
in renal tubules, which leads to an increase in sodium and water excretion. Sodium reabsorption 
occurs in different parts of the kidneys. The thick ascending part in Loop of Henle reabsorbs 
about 25% of the sodium, while the distal convoluted tubule reabsorbs about 5%. Loop diuretics 
(Furosemide) act on the thick ascending part in the Loop of Henle, therefore, they can inhibit the 
largest amount of sodium. Furosemide’s bioavailability can vary; it should be taken on an empty 
stomach to increase absorption. It is highly bound to plasma proteins (~95%). Almost half of 
furosemide administered is excreted into the urine, while the rest gets metabolized in the kidneys 
into glucuronide. Patients with renal dysfunction show an increase in the plasma half-life of 
furosemide, due to low excretion. Common adverse effects of Furosemide include hypovolemia, 
due to electrolyte imbalance, ototoxicity, and hypersensitivity. These adverse effects are higher 
and more potent in cardiovascular disease patients, in patients taking non-steroidal anti-
inflammatory drugs, and in the elderly. If Furosemide is administered during Warfarin treatment, 
Warfarin dose must be reduced due to the displacement action of Furosemide on the plasma 
proteins. (Oh and Han, 2015)  
Thiazides are another type of diuretics which act on the distal convoluted tubule by 




) co-transporter, which decrease sodium reabsorption. 
Consequently, the fluid loss is increased in the urine, which decreases plasma volume and 
extracellular fluid. The volume loss leads to decreased cardiac output, as well as decreased blood 
pressure. Thiazides are associated with hyperlipidemia, hyperglycemia, hypokalemia, 
hyperuricemia, as well as stimulation of the renin-angiotensin system. (Duarte and Cooper-
DeHoff, 2010) Chlorthalidone has a longer half-life than Hydrochlorothiazide, and was found to 
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decrease blood pressure better, especially at nighttime. Hydrochlorothiazide, however, is 
available in different combination preparations, which may support adherence in certain 
patients.(Allan et al., 2012) Indapamide is also another thiazide diuretic with possible calcium 
antagonist-like activities, which may contribute to the reduction in blood pressure. (Duarte and 
Cooper-DeHoff, 2010) Higher doses of thiazides tend to cause more adverse effects, such as 
hypokalemia; however, they tend to show more reduction in blood pressure. Patients taking 
diuretics should be aware of sodium intake, which should not exceed 1500mg/d. (Allan et al., 
2012) 
iii. Insulin Resistance, Type II Diabetes Treatment 
 
Insulin resistance is characterized by poor response to endogenous or exogenous insulin. 
Some patients require insulin of >1 unit/kg/day, which are considered insulin resistant; while 
patients who require >2 units/kg/day are considered severely resistant patients. The causes of 
insulin resistance vary; they include medications such as glucocorticoids and antipsychotics use, 
some endocrine disorders such as acromegaly and thyrotoxicosis, and physiological causes such 
as stress or pregnancy. (Church and Haines, 2016) 
Type II diabetes mellitus is associated with insulin resistance; it is a chronic metabolic 
disorder that has become an epidemic in some countries. Lifestyle and diet modifications reduce 
the incidence of type II diabetes mellitus, as well as maintaining a BMI of 25 kg/m
2
.  
Certain pharmacological agents have been used for the treatment of both insulin resistance, as 
well as diabetes mellitus type II.  
a. Biguanides 
 
Biguanides are a group of anti-diabetics, where Metformin is the most commonly used drug, 
especially in overweight and obese patients. It increases insulin sensitivity, suppresses the 
hepatic production of glucose, as well as decreasing glucose absorption from the gastrointestinal 
tract. Metformin has a low incidence of developing hypoglycemia, compared to other anti-
diabetics. There is, however, a risk of development of lactate acidosis with the administration of 





Sulfonylureas are other pharmacological agents used in the treatment of both insulin 
resistance and type II diabetes mellitus. They are a well-tolerated group of drugs; however, they 
stimulate the secretion of endogenous insulin, thus, hypoglycemia is a risk, especially in the 
elderly, with a 36% risk compared to younger patients. Glyburide, a long acting sulfonylurea, is 
usually avoided in elderly patients, due to the higher risk of developing hypoglycemia. On the 
other hand, Glipizide, a short acting sulfonylurea, is preferred in elderly. 
c. Meglitinides  
 
Meglitinides are secretagogues, similar in action to sulfonylureas – by stimulating 
endogenous insulin; however, their binding sites are different. Meglitinides act on the ATP-
dependent potassium channels in the pancreatic β-cells, thus stimulating insulin secretion from 
the β-cells. Meglitinides have a lower risk of hypoglycemia due to their rapid onset and short 
duration of action. They are usually given prior meals for post-prandial glucose control. 
Repaglinide is metabolized by the liver, thus, dose adjustment is not important in patients with 
renal insufficiency, as only minimal amount is excreted via the kidneys.  
d. Thiazolidinediones 
 
Thiazolidinedione is an insulin sensitizer, consisting only of Pioglitazone now. 
Pioglitazone does not cause hypoglycemia and could also be used in renal impaired patients; it is 
also well tolerated in elderly. However, peripheral edema and fluid retention may occur, and 
therefore Pioglitazone should be avoided in elderly with congestive heart failure.  
e. Alpha-glucosidase Inhibitors 
 
Alpha-glucosidase inhibitors, such as Acarbose, have not been widely used; yet, they are 
safe and effective. They are effective for postprandial hyperglycemia; however, they should not 
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be administered to patients with renal impairment. Adverse effects such as diarrhea and 
flatulence may occur, and thus, limit its administration. 
f. GLP-1 
 
Glucagon-like peptide 1 (GLP-1), such as Liraglutide and Exenatide, which are incretin-
based therapy, are targeted to improve body weight control, as well as glycemic control.  They 
could be used as monotherapy, as well as in combination with other oral hypoglycemic agents. 




Dipeptidyl-peptidase IV (DPP IV) inhibitors inhibit the dipeptidyl peptidase enzyme, 
which inactivates GLP-1, increasing its active levels, and therefore improves the function and 
glycemic control in type II diabetes mellitus. They can be used as monotherapy, as well as in 
combination with other anti-diabetogenic agents such as Metformin or Insulin. They are usually 
well tolerated with low risk of hypoglycemia; however, they are an expensive therapy 
alternative.  
h. Human Insulin 
 
Insulin could be used as monotherapy or in combination. It comes in many injectable 
forms, such as short-acting, intermediate acting, or long-acting. Long-acting forms are better due 
to lower risk of hypoglycemia, compared to the short-acting analogues. Therapy with basal 
insulin could be useful in case some beta cells function still remains. (Olokoba et al., 2012) 
Insulin was used as the ideal therapy for insulin resistance; however, some patients could not 
reach the glycemic control, where others were intolerant of the adverse effects such as 
hypoglycemia and weight gain, and therefore, other pharmacological agents are recommended. 
(Church and Haines, 2016) 
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Type II diabetes mellitus could be prevented by lifestyle modification as well as diet 
control. Since there is no cure for the disease, management of diabetes should be chosen 
accordingly to the lifestyle of the patient. (Olokoba et al., 2012) 
 
VII. Latest new approaches for Metabolic Syndrome Treatment 
 
Current therapy for metabolic syndrome is effective and shows good therapeutic results; 
however, there is always a need for novel techniques and approaches towards the risk factors 
associated with the syndrome. 
a. Ketanserin  
 
Several new approaches have been found for treatment of hypertension. Ketanserin is a 
specific 5-Hyroxytryptamine (5-HT2) receptor antagonist. 5-HT has a direct smooth muscle 
action and causes vasoconstriction, as well as stimulating the vasoactive properties of 
noradrenaline and angiotensin. 5-HT2 subtype is specific to the vasoconstrictive action.  
Ketanserin has been shown to reduce blood pressure in animals and has shown efficacy when 
used acutely in humans (Hedner et al.). Ketanserin has also been shown to have α-adrenergic 
blocking effect, as well as CNS inhibitory effect and interference with the renin-angiotensin-
aldosterone system; however, the antihypertensive effect of Ketanserin is not fully based on the 
α-adrenergic blockage. In comparison with the classic α1-adrenergic blocking agent, Prazosin, 
Ketanserin was shown to reduce the blood pressure similarly; however, there was no first dose 
effect of postural hypotension, tachycardia, or increased catecholamines that are usually present 
with Prazosin first dose administration. Moreover, in the long term therapy of Prazosin, there 
were no changes in the heart rate, but with Ketanserin long term therapy, heart rate was reduced. 
However, prolongation of the QT interval during chronic treatment of Ketanserin has been 
recorded; causing clinical complications due to the possible development of ventricular 
arrhythmias (Donnelly et al.). 
According to a study of patients with mild to moderate hypertension, the blood pressure 
and heart rates in both standing and lying down patients have shown to decrease after Ketanserin 
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treatment of 40mg daily for 1 week. The patients tested did not complain of any serious adverse 
effects; however, some symptoms of dizziness, fatigue and lightheadedness were recorded. 
These symptoms usually appeared 1-2 hours after administration and were gone after continued 
treatment. Therefore, there has been shown significant reduction in blood pressure after 
administration of Ketanserin (Hedner et al.).   
b. Cromakalim 
 
Another novel therapy for hypertension is Cromakalim (BRL 34915); a smooth muscle 
relaxant that works by enhancing the potassium efflux from the cells, causing hyperpolarization 
of the cell membrane. Due to its vaso-relaxant effect, it has shown a decrease in blood pressure 
in laboratory animals. It has also been found; according to a study that Cromakalim has an 
inhibitory effect on the histamine induced vasoconstriction, and could be used as a 
bronchodilator in asthma (Arch J.R.S, et al.). According to a study, Cromakalim was compared 
to Nifedipine, a Ca
2+ 
blocking agent, and was found to inhibit the noradrenaline-induced 
contractions in aorta’s of rabbits, in comparison with Nifedipine. The effects of Cromakalim 
could be antagonized by glibenclamide, an oral anti-diabetic drug, or by increasing the 
extracellular Ca
2+




free physiological salt solution by the 
inhibition of Ca
2+ 
refilling and release from the noradrenaline-releasable Ca
2+  
stores; however, 
Nifedipine was found ineffective (Bray et al.).   
 
c. Tesofensine  
 
A new therapy for obesity is the novel drug Tesofensine, which is a serotonin 
noradrenaline dopamine reuptake inhibitor. It is currently still under development, it completed 
Phase I and II from clinical trials. The mechanism of action is mainly due to the appetite 
suppression effect, as well as increasing the resting energy expenditure. According to Phase II 
trials, it showed weight loss effects compared to other anti-obesity drugs.  It is currently in Phase 
III of clinical trials; however, the adverse effects may be a drawback. These include dry mouth, 
headache, insomnia, gastrointestinal effects, and an increase in blood pressure and heart rate. 
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Another emerging therapy for obesity is the focus on receptor-interacting-protein 140 (RIP140); 
which is a nuclear hormone co-repressor that regulates fat accumulation. It interacts with other 
nuclear receptors such as estrogen, thyroid hormone and retinoic acid receptors. Silencing the 
RIP140 in animals results in long lasting weight loss, as well as increased metabolic rate. It is 
still being developed for treatment against obesity and type II diabetes mellitus.  
d. CDDO-Imidazole 
 
In addition to the previous emerging therapies, there is an inhibitor of adipogenesis; 
CDDO-Imidazole, which is currently still in clinical trials. It activates the nuclear factor 
(erythroid-derived 2) - like 2 (NFE2L2); which is a transcription factor that regulates the 
expression of antioxidant proteins to protect again oxidative damage. Activating the NFE2L2 
results in increased mitochondrial biogenesis, reduced adipogenesis, as well as increased energy 
metabolism. This drug, in rodents, has been shown to reduce body weight and body fat, as well 
as diminishing hepatic lipid accumulation. (Martin et al., 2015) 
e. Technosphere Insulin 
 
There are a few new approaches to the treatment of insulin resistance, and type II 
diabetes. Technosphere insulin; a novel formulation of regular human insulin, is designed for 
pulmonary administration of insulin through inhalation. Technosphere is prepared by loading 
human insulin onto micro particles of fumaryl diketopiperazine (FDKP), which is a new 
excipient. (Rave et al., 2008) the Technosphere particles have high porosity, as well as high 
surface area for adsorption of other drugs; the Technosphere insulin powder is made of insulin 
that is adsorbed onto the Technosphere particle with a size suitable for deep lung delivery. FDKP 
drives the diffusion across the pulmonary membranes after the Technosphere particles dissolve 
and cause a high concentration of insulin. FDKP may also act as a penetration enhancer by 
dilating the tight junctions and opening up paracellular pathways between cells to enhance 
absorption. (Angelo et al.. 2009) 
Technosphere insulin has been compared with subcutaneous regular human insulin, 
which showed a rapid onset of action, and short duration of the inhaled form. The maximum 
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serum insulin concentration occurred after almost 10-14 minutes of inhalation, and the major 
glucose-lowering effect occurred after almost 3 hours of administration. Variability in the insulin 
effect depends on the variability of the pharmacokinetics (absorption rate) and 
pharmacodynamics (metabolic response) of the insulin.  The subcutaneous insulin absorption 
depends on many factors such as blood flow at the area of injection, the injection site, the depth 
of the injection, fat and other connective tissue present at the injection site, temperature affecting 
blood flow, and the physicochemical properties of the insulin injected. However, the inhaled 
insulin has decreased the insulin variability; as insulin is easily and faster absorbed from the 
pulmonary tissues. The blood flow in the lung’s epithelium is more homogenous, in comparison 
to the subcutaneous tissue, which allows faster absorption of the insulin. There has been no 
severe adverse effects reported; most patients, however, complained of cough, which is a 
common phenomenon with most of inhaled drugs. (Rave et al., 2008) 
f. Insulin-chitosan Complex 
 
Another new strategy towards oral insulin is the insulin-chitosan complex; which is based 
on a nanolayer encapsulation of insulin in chitosan. The aim of this new strategy is based on the 
unpredictable release and burst of insulin in the intestine, from the ordinary oral formulation, 
which increases hypoglycemia risk. The chitosan/heparin multilayer coatings are deposited onto 
the insulin-chitosan nanoparticle complex; in the presence of polyethylene glycol (PEG), which 
prevents insulin particles from being partially dissolved during the layer deposition, as well as 
promoting the retention of the precipitated insulin; increasing the capsule loading capacity. This 
leads to a sustained-release formulation, where the nanolayer encapsulation leads to increased 
stability, and decreased solubility at acidic pH. Chitosan is a naturally occurring polysaccharide, 
which enhances bioadhesive properties, as well as transmucosal absorption of insulin. The 
mucoadhesive property of chitosan extends the contact time and promotes cellular permeability. 




Figure 5. Scheme of nanocoating of insulin or insulin-chitosan micoparticles in the 
nonengineered polysaccharide capsules. 
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014370/ 
In the typical release experiment, the insulin-chitosan is coated seven times by the 
chitosan/heparin layers, with chitosan as the outermost layer. The diameter of the insulin-
chitosan microparticle was almost 1µm, which showed no difference compared to the 
nonencapsulated insulin; however, the insulin-chitosan microparticles were more solid with a 
crystal-like appearance, compared to the insulin particles which are loosely formed. The 
nanolayer encapsulation is a novel strategy, which helps the fast reduction of blood glucose, 
preventing sudden hypoglycemia, and making the formulation safer for oral administration. This 
strategy increases the intestinal absorption of the insulin; however, more extensive clinical 
testing is required for clinical development. (Song et al., 2014) 
Imeglimin, from the family of Glimins, a tetrahydrotriazene compound, is a drug still in 
development for the treatment of type II diabetes mellitus. It is shown to act on the three main 
physiological components of type II diabetes; impaired glucose uptake by muscle tissue, 
excessive glucogenesis by the hepatic cells, and an increase in the apoptosis of the β-cells. 
(Marín-Peñalver et al., 2016) After review of the agents used to treat type II diabetes mellitus, 
Imeglimin was found to be the only agent targeting the three main defects in this disease. In 
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animals’ studies, it has been shown to reduce fasting plasma glucose levels, as well as inhibiting 
hepatic glucose production, similar to Metformin mechanism. It has also been found to stimulate 
glucose uptake by skeletal muscles, and also reduce liver steatosis. Moreover, it has been found 
to have a similar mechanism to that of DPP IV inhibitors, with the glucose-dependent insulin 
secretion mechanism. This therapy is still under development, where further evidence is needed 
for FDA approval, however, it is hoped to be used either as an alternative therapy to type II 
diabetes, or in combination with other known therapies. (Vuylsteke et al., 2015) 
g. PPARs 
 
Peroxisome proliferator-activated receptors (PPARs) are responsible in the metabolic 
regulation of triglycerides, blood glucose, and abdominal obesity; therefore, they may play a role 
in therapeutic approaches to metabolic syndrome. PPAR-α, a type of PPARs which is 
predominately found in the liver, and also in the muscles and heart, are effective in lowering 
triglycerides levels by affecting triglycerides catabolism. Fibrates and omega 3 fatty acids are 
types of PPAR-α agonists. (Botta et al., 2018) The activation of PPAR-α occurs in the liver 
under energy deprivation, with the main use of increasing ATP production from β-oxidative 
phosphorylation. PPAR-α has also been found to have anti-inflammatory properties; which 
suggests that activation of PPAR-α improves both insulin resistance and obesity. Treatment with 
PPAR-α agonists has been shown to increase the expression of adiponectin, as well as tumor 
necrosis factor α. PPAR-β/δ, another type of PPARs, has also been found to have anti-
inflammatory properties, where it reduces the proinflammatory markers, such as nuclear factor 
kappa B, in adipocytes and macrophages. (Corrales et al., 2018)  It is the least characterized 
PPAR, yet it is expressed the most in skeletal muscles during fasting; studies have suggested it is 
tightly related to physical exercise. (Botta et al., 2018) PPAR-γ, the third type of PPARs, is 
expressed mostly in adipose tissues, both brown and white; playing a role in adipogenesis, 
thermogenesis, and in facilitating fat storage. It is important in the regulation of fat storage as 
triglycerides, as well as energy homeostasis; any alterations in the expression increases 
susceptibility to lipodystrophy, type II diabetes mellitus, and insulin resistance. There are 2 types 
of PPAR- γ, which are predominant in adipose tissues; PPAR- γ1, which is distributed the most, 
has a metabolic role in intestines, liver, macrophages, pancreatic β-cells, and adipose tissues, 
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while PPAR- γ2 is induced in the liver and skeletal muscles in conditions such as long-term 
obesity and overnutrition. (Corrales et al., 2018) Bone loss and high bone marrow adiposity 
occur due to the upregulation of PPAR- γ. Thiazolidinediones, agonists of PPAR-γ, have 
hypoglycemic effects, as well as improving insulin resistance in obesity; they also have anti-
inflammatory effects on adipose tissues. However, they made lead to weight gain, as well as 
other adverse effects such as increase in plasma creatinine levels, formation of gallstones, 
myopathy, and some drug-drug interactions – such as Gemfibrozil. (Botta et al., 2018) 
 
h. Cholesteryl Esterase Transfer Protein Inhibitors 
Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from 
HDL to LDL and VLDL; thus, increasing LDL and VLDL levels while decreasing HDL levels. 
A deficiency in CETP leads to an increase in HDL, while in some pathological states, such as 
atherosclerosis, are associated with an increase in CETP. CETP inhibitors, in comparison with 
statins, not only increase HDL levels, but also reduce LDL levels, which is absent in the statins 
treatment. There are two developed compounds, Torcetrapib and Dalcetrapib, that were 
discontinued due to off-target effects of Torcetrapib, by stimulation of aldosterone system; 
leading to an increase in blood pressure, or in the case of Dalcetrapib, due to the cardiovascular 
harm. There are other CETP inhibitors, such as Anacetrapib and Evacetrapib that show 
promising results (Remaley et al., 2014). Anacetrapib was shown to have significant 
improvement in lipids profile and a decrease in the cardiovascular risk in statin-treated patients. 
This could be proof that Anacetrapib is the optimal therapeutic alternative for hypolipidemic 
treatment in high-risk patients on statin treatment, if the trials show positive results on the 
cardiovascular effects (Filippatos et al., 2017).  
i. Apo-AI Inducers 
Apo-AI, also called preβ-HDL, is a lipid-poor, main constituent of HDL. It promotes 
cholesterol efflux from the cell membrane, which then matures to HDL. The induction of Apo-
AI increases HDL, which is a mechanism similar to fibrates and nicotinic acid. A novel 
compound, RVX-208, has been found to induce Apo-AI as well. However, the primary outcome 
of the drug on atheroma volume in statin-treated patients failed, and therefore, the data from the 
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clinical trials were not published yet to determine whether it is a viable drug for pharmacological 
use in raising HDL (Remaley et al., 2014).   
j. PCSK9 Inhibitors 
Despite the widely available treatments for LDL lowering, patients who are intolerant to 
statins develop CVD risks, or suffer hypercholesterolemia. Thus, the FDA has approved two 
novel therapies, Evolocumab and Alirocumab, which inactivate the proprotein convertase 
subtilsin-kexin type 9 (PCSK9), which is a hepatic protease that attaches to the LDL receptors 
and promotes its metabolism and degradation; this could lower LDL levels 50%-60% compared 
to statins therapy. Alirocumab had undergone three phase I trials; and it was observed that 
Alirocumab, in comparison with statins, remained effective for a longer period of time. Some 
adverse effects were reported with the use of Alirocumab, the most common were allergic 
reactions and elevated liver enzymes. Other adverse effects such as injection site reactions 
(itching and swelling), urinary tract infections, and diarrhea occurred as well. In Evolocumab 
administration, similar side effects were reported as Alirocumab; however, some adverse effects 
lead to the discontinuation of the drug, such as myalgia, dizziness, and nausea. Palpitations and 
angina pectoris were associated with Evolocumab as well. Despite the adverse drug effects 
occurring from the novel therapy of PCSK9 inhibitors, they show a promising future for patients 
who are intolerant to statins therapy (Chaudhary et al., 2017).   
k. Polypills 
 
There is an emerging concept of the use of “polypills” in the treatment of metabolic 
syndrome; which is a pill consisting of more than one active ingredient that would target 
different cardiovascular diseases. There was a study regarding a “polypill” that consisted of 
combining aspirin, a β-blocker, an ACE inhibitor, a diuretic, and a folic acid; all contained in one 
tablet. The concept of polypill may be beneficial in improving adherence in patients taking more 
than one medication for the treatment of metabolic syndrome, as well as other cardiovascular 
diseases, which leads to the reduction of polypharmacy in such patients. Another advantage to 
the polypill is the decreased cost for both the patient and the society. Currently there are a few 
polypills under development, one of which consists of aspirin, statin, β-blocker, and ACE 
inhibitor. According to a study, patients with cardiovascular risk factors received Polycap, which 
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is a pill consisting of hydrochlorothiazide 12.5 mg, atenolol 50 mg, Ramipril 5mg, simvastatin 
5mg, and aspirin 100mg. The Polycap was shown to reduce blood pressure, similarly to the 
antihypertensives taken separately; however, the reduction in cholesterol was less than patients 
who received simvastatin alone. There appeared to be no drug-drug interactions, and no serious 
adverse effects were seen. The concept of Polypill seems to be developing as it is an attractive 


















VIII. Conclusion  
 
Metabolic syndrome, also known as insulin resistance syndrome, is a cluster of diseases 
including; central obesity, insulin resistance, atherogenic dyslipidemia, elevated blood pressure, 
and prothrombic inflammatory states. There are several risk factors for the development of the 
syndrome and associated diseases; non-modifiable factors include environmental and genetics, 
while other modifiable risk factors include diet, smoking, and lack of exercise. The main 
therapeutic approach towards the disease is the targeting of the risk factors associated with the 
syndrome, such as the treatment and management of the blood pressure and blood glucose levels, 
the control of the body weight, and other general therapy such as diet and exercise. Despite the 
general, already known therapy for the treatment of risk factors associated with metabolic 
syndrome; there are emerging new therapies still under development. Some therapies have 













IX. References  
 
[Table], Common Generic and Brand Names for ACE Inhibitors and ARBs. Agency for 
Healthcare Research and Quality (US), July 2010, 
https://www.ncbi.nlm.nih.gov/books/NBK51219/table/cerconsangina.tu1/. 
Aganović, Izet, and Tina Dušek. “Pathophysiology of Metabolic Syndrome.” EJIFCC, vol. 18, 
no. 1, International Federation of Clinical Chemistry and Laboratory Medicine, Feb. 2007, 
pp. 3–6, http://www.ncbi.nlm.nih.gov/pubmed/29632461. 
Allan, G. Michael, et al. “Best Thiazide Diuretic for Hypertension.” Canadian Family Physician 
Medecin de Famille Canadien, vol. 58, no. 6, College of Family Physicians of Canada, June 
2012, p. 653, http://www.ncbi.nlm.nih.gov/pubmed/22859628. 
Angelo, Robert, et al. “Technosphere Insulin: Defining the Role of Technosphere Particles at the 
Cellular Level.” Journal of Diabetes Science and Technology, vol. 3, no. 3, Diabetes 
Technology Society, May 2009, pp. 545–54, doi:10.1177/193229680900300320. 
Barter, Philip J., et al. “Effect of Statins on HDL-C: A Complex Process Unrelated to Changes in 
LDL-C: Analysis of the VOYAGER Database.” Journal of Lipid Research, vol. 51, no. 6, 
American Society for Biochemistry and Molecular Biology, June 2010, pp. 1546–53, 
doi:10.1194/jlr.P002816. 
Beilby, John. “Definition of Metabolic Syndrome: Report of the National Heart, Lung, and 
Blood Institute/American Heart Association Conference on Scientific Issues Related to 
Definition.” The Clinical Biochemist Reviews, vol. 25, no. 3, The Australian Association of 
Clinical Biochemists, 2004, p. 195, 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880831/. 
Binesh Marvasti, T., and Kh Adeli. “Pharmacological Management of Metabolic Syndrome and 
Its Lipid Complications.” Daru : Journal of Faculty of Pharmacy, Tehran University of 




Botta, Margherita, et al. “PPAR Agonists and Metabolic Syndrome: An Established Role?” 
International Journal of Molecular Sciences, vol. 19, no. 4, Multidisciplinary Digital 
Publishing Institute  (MDPI), Apr. 2018, doi:10.3390/ijms19041197. 
Bray, K. M., et al. “Differences between the Effects of Cromakalim and Nifedipine on Agonist-
Induced Responses in Rabbit Aorta.” British Journal of Pharmacology, vol. 102, no. 2, 
Wiley-Blackwell, Feb. 1991, pp. 337–44, http://www.ncbi.nlm.nih.gov/pubmed/2015418. 
Callaghan, Brian, and Eva Feldman. “The Metabolic Syndrome and Neuropathy: Therapeutic 
Challenges and Opportunities.” Annals of Neurology, vol. 74, no. 3, Sept. 2013, pp. 397–
403, doi:10.1002/ana.23986. 
Cassis, Lisa A., et al. “Local Adipose Tissue Renin-Angiotensin System.” Current Hypertension 
Reports, vol. 10, no. 2, NIH Public Access, Apr. 2008, pp. 93–98, 
http://www.ncbi.nlm.nih.gov/pubmed/18474174. 
Chaudhary, Rahul, et al. “PCSK9 Inhibitors: A New Era of Lipid Lowering Therapy.” World 
Journal of Cardiology, vol. 9, no. 2, Baishideng Publishing Group Inc, Feb. 2017, pp. 76–
91, doi:10.4330/wjc.v9.i2.76. 
Cheung, Bernard Man Yung, et al. “Safety of Antiobesity Drugs.” Therapeutic Advances in 
Drug Safety, vol. 4, no. 4, SAGE Publications, Aug. 2013, pp. 171–81, 
doi:10.1177/2042098613489721. 
Church, Timothy J., and Stuart T. Haines. “Treatment Approach to Patients With Severe Insulin 
Resistance.” Clinical Diabetes : A Publication of the American Diabetes Association, vol. 
34, no. 2, American Diabetes Association, Apr. 2016, pp. 97–104, 
doi:10.2337/diaclin.34.2.97. 
Cojocaru, Manole, et al. “Metabolic Syndrome in Rheumatoid Arthritis.” Maedica, vol. 7, no. 2, 
Amaltea Medical, Editura Magister, June 2012, pp. 148–52, 
http://www.ncbi.nlm.nih.gov/pubmed/23399930. 
Corrales, Patricia, et al. “PPARs and Metabolic Disorders Associated with Challenged Adipose 
Tissue Plasticity.” International Journal of Molecular Sciences, vol. 19, no. 7, 
51 
 
Multidisciplinary Digital Publishing Institute  (MDPI), July 2018, 
doi:10.3390/ijms19072124. 
de Kloet, Annette D., et al. “The Renin Angiotensin System and the Metabolic Syndrome.” 
Physiology & Behavior, vol. 100, no. 5, NIH Public Access, July 2010, pp. 525–34, 
doi:10.1016/j.physbeh.2010.03.018. 
Devi, S. Asha, and B. Jyothi. “Dyslipidemia in Metabolic Syndrome: An Overview of 
Lipoprotein-Related Disorders.” International Journal of Cardiology and Lipidology 
Research, vol. 4, 2017, 
https://pdfs.semanticscholar.org/c19f/2f10e742f62b0a396b3b3d882a3cb26e68ae.pdf. 
Donnelly, R., et al. “Acute and Chronic Ketanserin in Essential Hypertension: Antihypertensive 
Mechanisms and Pharmacokinetics.” British Journal of Clinical Pharmacology, vol. 24, no. 
5, Wiley-Blackwell, Nov. 1987, pp. 599–606, 
http://www.ncbi.nlm.nih.gov/pubmed/3325090. 
Duarte, Julio D., and Rhonda M. Cooper-DeHoff. “Mechanisms for Blood Pressure Lowering 
and Metabolic Effects of Thiazide and Thiazide-like Diuretics.” Expert Review of 
Cardiovascular Therapy, vol. 8, no. 6, NIH Public Access, June 2010, pp. 793–802, 
doi:10.1586/erc.10.27. 
Femlak, Marek, et al. “The Role and Function of HDL in Patients with Diabetes Mellitus and the 
Related Cardiovascular Risk.” Lipids in Health and Disease, vol. 16, no. 1, BioMed 
Central, Oct. 2017, p. 207, doi:10.1186/s12944-017-0594-3. 
Fg, Nazirov, et al. Atherosclerosis and Metabolic Syndrome-Significance of Inflammation, 
Urgency of Weight Loss and Extracorporeal Removal of Proinflammatory and 
Proatherogenic Substances. 2017, doi:10.4172/2329-6607.1000227. 
Filippatos, Theodosios D., et al. “Anacetrapib, a New CETP Inhibitor: The New Tool for the 
Management of Dyslipidemias?” Diseases (Basel, Switzerland), vol. 5, no. 4, 




Freeman, Andrew J., et al. “Novel Approaches for Treating Hypertension.” F1000Research, vol. 
6, Faculty of 1000 Ltd, 2017, p. 80, doi:10.12688/f1000research.10117.1. 
G, Thaman R., and Arora G. P. “Metabolic Syndrome: Definition and Pathophysiology-the 
Discussion Goes on! Metabolic Syndrome: Definition and Pathophysiology-the Discussion 
Goes on! Introduction and Definition.” Journal of Physiology and Pharmacology Advances 
THAMAN AND ARORA 48 J. Phys. Pharm. Adv, vol. 2013, no. 3, 2013, pp. 48–56, 
doi:10.5455/jppa.20130317071355. 
Goldenberg, Ilan, et al. “Update on the Use of Fibrates: Focus on Bezafibrate.” Vascular Health 
and Risk Management, vol. 4, no. 1, Dove Press, 2008, pp. 131–41, 
http://www.ncbi.nlm.nih.gov/pubmed/18629356. 
Han, Thang S., and Mike Ej Lean. “A Clinical Perspective of Obesity, Metabolic Syndrome and 
Cardiovascular Disease.” JRSM Cardiovascular Disease, vol. 5, SAGE Publications, 2016, 
p. 2048004016633371, doi:10.1177/2048004016633371. 
Hedner, T., et al. “Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in 
Essential Hypertension.” British Journal of Clinical Pharmacology, vol. 16, no. 2, Wiley-
Blackwell, Aug. 1983, pp. 121–25, http://www.ncbi.nlm.nih.gov/pubmed/6615685. 
Herman, Linda L., and Khalid Bashir. “Angiotensin Converting Enzyme Inhibitors (ACEI).” 
StatPearls, StatPearls Publishing, 2019, http://www.ncbi.nlm.nih.gov/pubmed/28613705. 
Ho, Minh-Minh, et al. “Macrophage Molecular Signaling and Inflammatory Responses during 
Ingestion of Atherogenic Lipoproteins Are Modulated by Complement Protein C1q.” 
Atherosclerosis, vol. 253, NIH Public Access, 2016, pp. 38–46, 
doi:10.1016/j.atherosclerosis.2016.08.019. 
Huang, Paul L. “A Comprehensive Definition for Metabolic Syndrome.” Disease Models & 
Mechanisms, vol. 2, no. 5–6, Company of Biologists, 2009, pp. 231–37, 
doi:10.1242/dmm.001180. 
J.R.S. Arch, 1D.R. Buckle, J. Bumstead, 2G.D. Clarke, J. F. Taylor &. S. G. Taylor. Evaluation 
of the Potassium Channel Activator Cromakalim (BRL 34915) as a Bronchodilator in the 
53 
 
Guinea-Pig: Comparison with Nifedipine. 
https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC1854211&blobtype=pdf. 
Accessed 19 Mar. 2019. 
Kamanna, V. S., et al. “The Mechanism and Mitigation of Niacin-Induced Flushing.” 
International Journal of Clinical Practice, vol. 63, no. 9, Wiley-Blackwell, Sept. 2009, pp. 
1369–77, doi:10.1111/j.1742-1241.2009.02099.x. 
Karanchi, Harsha, and Kathleen Wyne. “Hypertriglyceridemia.” StatPearls, StatPearls 
Publishing, 2019, http://www.ncbi.nlm.nih.gov/pubmed/29083756. 
Kassi, Eva, et al. “Metabolic Syndrome: Definitions and Controversies.” BMC Medicine, vol. 9, 
BioMed Central, May 2011, p. 48, doi:10.1186/1741-7015-9-48. 
Kaur, Jaspinder. “A Comprehensive Review on Metabolic Syndrome.” Cardiology Research and 
Practice, vol. 2014, Hindawi Limited, 2014, p. 943162, doi:10.1155/2014/943162. 
---. “A Comprehensive Review on Metabolic Syndrome.” Cardiology Research and Practice, 
vol. 2014, Hindawi Limited, 2014, p. 943162, doi:10.1155/2014/943162. 
Kirk, Erik P., and Samuel Klein. “Pathogenesis and Pathophysiology of the Cardiometabolic 
Syndrome.” Journal of Clinical Hypertension (Greenwich, Conn.), vol. 11, no. 12, NIH 
Public Access, Dec. 2009, pp. 761–65, doi:10.1111/j.1559-4572.2009.00054.x. 
Kolovou, G. D., and K. K. Anagnostopoulou. “Pathophysiology of Dyslipidaemia in the 
Metabolic Syndrome.” Postgrad Med J, vol. 81, 2005, pp. 358–66, 
doi:10.1136/pgmj.2004.025601. 
Kotsis, Vasilios, et al. “Mechanisms of Obesity-Induced Hypertension.” Hypertension Research, 
vol. 33, no. 5, May 2010, pp. 386–93, doi:10.1038/hr.2010.9. 
Lee, Sang-Hyun, et al. “Relationship between Metabolic Syndrome and Rheumatoid Arthritis.” 
Korean Journal of Family Medicine, vol. 37, no. 1, Korean Academy of Family Medicine, 
Jan. 2016, pp. 44–50, doi:10.4082/kjfm.2016.37.1.44. 
Marín-Peñalver, Juan José, et al. “Update on the Treatment of Type 2 Diabetes Mellitus.” World 
54 
 
Journal of Diabetes, vol. 7, no. 17, Baishideng Publishing Group Inc, Sept. 2016, pp. 354–
95, doi:10.4239/wjd.v7.i17.354. 
Martin, Kathleen A., et al. “New Targets to Treat Obesity and the Metabolic Syndrome.” 
European Journal of Pharmacology, vol. 763, no. Pt A, NIH Public Access, Sept. 2015, pp. 
64–74, doi:10.1016/j.ejphar.2015.03.093. 
Matfin, Glenn. “Developing Therapies for the Metabolic Syndrome: Challenges, Opportunities, 
And… the Unknown.” Therapeutic Advances in Endocrinology and Metabolism, vol. 1, no. 
2, SAGE Publications, Apr. 2010, pp. 89–94, doi:10.1177/2042018810375812. 
McKeever, Rita G., and Richard J. Hamilton. “Calcium Channel Blockers.” StatPearls, 
StatPearls Publishing, 2019, http://www.ncbi.nlm.nih.gov/pubmed/29494080. 
McTaggart, Fergus, and Peter Jones. “Effects of Statins on High-Density Lipoproteins: A 
Potential Contribution to Cardiovascular Benefit.” Cardiovascular Drugs and Therapy, vol. 
22, no. 4, Springer, Aug. 2008, pp. 321–38, doi:10.1007/s10557-008-6113-z. 
Nerkar, Damini, et al. “Metabolic Syndrome Associated Complications.” International Journal 
of Pharmacy and Pharmaceutical Sciences, 2015. 
Nolan, Paul B., et al. “Prevalence of Metabolic Syndrome and Metabolic Syndrome Components 
in Young Adults: A Pooled Analysis.” Preventive Medicine Reports, vol. 7, Elsevier, Sept. 
2017, pp. 211–15, doi:10.1016/j.pmedr.2017.07.004. 
Oh, Hye-Mi, et al. “The Relationship between Metabolic Syndrome and Cognitive Function.” 
Korean Journal of Family Medicine, vol. 32, no. 6, Korean Academy of Family Medicine, 
Sept. 2011, pp. 358–66, doi:10.4082/kjfm.2011.32.6.358. 
Oh, Se Won, and Sang Youb Han. “Loop Diuretics in Clinical Practice.” Electrolyte & Blood 
Pressure : E & BP, vol. 13, no. 1, Korean Society of Electrolyte Metabolism, June 2015, pp. 
17–21, doi:10.5049/EBP.2015.13.1.17. 
Olokoba, Abdulfatai B., et al. “Type 2 Diabetes Mellitus: A Review of Current Trends.” Oman 




Ozawa, Yuri, et al. “New Generation Calcium Channel Blockers in Hypertensive Treatment.” 
Current Hypertension Reviews, vol. 2, no. 2, NIH Public Access, May 2006, pp. 103–11, 
doi:10.2174/157340206776877370. 
Paley, Carole A., and Mark I. Johnson. “Abdominal Obesity and Metabolic Syndrome: Exercise 
as Medicine?” BMC Sports Science, Medicine & Rehabilitation, vol. 10, BioMed Central, 
2018, p. 7, doi:10.1186/s13102-018-0097-1. 
Perlot, Thomas, and Josef M. Penninger. “ACE2 – From the Renin–angiotensin System to Gut 
Microbiota and Malnutrition.” Microbes and Infection, vol. 15, no. 13, Elsevier Masson, 
Nov. 2013, pp. 866–73, doi:10.1016/J.MICINF.2013.08.003. 
Phan, Binh An P., et al. “Ezetimibe Therapy: Mechanism of Action and Clinical Update.” 
Vascular Health and Risk Management, vol. 8, Dove Press, 2012, pp. 415–27, 
doi:10.2147/VHRM.S33664. 
Pitsavos, Christos, et al. “Diet, Exercise and the Metabolic Syndrome.” The Review of Diabetic 
Studies : RDS, vol. 3, no. 3, Society for Biomedical Diabetes Research, 2006, pp. 118–26, 
doi:10.1900/RDS.2006.3.118. 
Ramkumar, Satish, et al. “Statin Therapy: Review of Safety and Potential Side Effects.” Acta 
Cardiologica Sinica, vol. 32, no. 6, Taiwan Society of Cardiology, Nov. 2016, pp. 631–39, 
doi:10.6515/ACS20160611A. 
Rave, Klaus, et al. “Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular 
Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes.” 
Journal of Diabetes Science and Technology, vol. 2, no. 2, Diabetes Technology Society, 
Mar. 2008, pp. 205–12, doi:10.1177/193229680800200206. 
Re, Richard N. “Obesity-Related Hypertension.” The Ochsner Journal, vol. 9, no. 3, Ochsner 
Clinic, L.L.C. and Alton Ochsner Medical Foundation, 2009, pp. 133–36, 
http://www.ncbi.nlm.nih.gov/pubmed/21603428. 
Remaley, Alan T., et al. “Novel Concepts in HDL Pharmacology.” Cardiovascular Research, 
vol. 103, no. 3, Oxford University Press, Aug. 2014, pp. 423–28, doi:10.1093/cvr/cvu141. 
56 
 
RIVIN, A. U. “Hypercholesterolemia. Use of Niacin and Niacin Combinations in Therapy.” 
California Medicine, vol. 96, no. 4, BMJ Publishing Group, Apr. 1962, pp. 267–69, 
http://www.ncbi.nlm.nih.gov/pubmed/14492608. 
Schofield, Jonathan D., et al. “Diabetes Dyslipidemia.” Diabetes Therapy, vol. 7, no. 2, Springer, 
2016, p. 203, doi:10.1007/S13300-016-0167-X. 
Shipman, Kate E., et al. “Use of Fibrates in the Metabolic Syndrome: A Review.” World Journal 
of Diabetes, vol. 7, no. 5, Baishideng Publishing Group Inc, Mar. 2016, pp. 74–88, 
doi:10.4239/wjd.v7.i5.74. 
Song, Lei, et al. “Nanolayer Encapsulation of Insulin-Chitosan Complexes Improves Efficiency 
of Oral Insulin Delivery.” International Journal of Nanomedicine, vol. 9, Dove Press, 2014, 
pp. 2127–36, doi:10.2147/IJN.S59075. 
Stafylas, Panagiotis C., and Pantelis A. Sarafidis. “Carvedilol in Hypertension Treatment.” 
Vascular Health and Risk Management, vol. 4, no. 1, Dove Press, 2008, pp. 23–30, 
http://www.ncbi.nlm.nih.gov/pubmed/18629377. 
Trabulo, Daniel, et al. “Metabolic Syndrome and Colorectal Neoplasms: An Ominous 
Association.” World Journal of Gastroenterology, vol. 21, no. 17, Baishideng Publishing 
Group Inc, May 2015, pp. 5320–27, doi:10.3748/wjg.v21.i17.5320. 
Tucker, William D., and Pramod Theetha Kariyanna. “Selective Beta-1-Blockers.” StatPearls, 
StatPearls Publishing, 2019, http://www.ncbi.nlm.nih.gov/pubmed/29763157. 
Vergès, Bruno. “Pathophysiology of Diabetic Dyslipidaemia: Where Are We?” Diabetologia, 
vol. 58, no. 5, Springer, May 2015, pp. 886–99, doi:10.1007/s00125-015-3525-8. 
Vuylsteke, Valerie, et al. “Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.” 
Drugs in R&D, vol. 15, no. 3, Springer, Sept. 2015, pp. 227–32, doi:10.1007/s40268-015-
0099-3. 
Wilcox, Gisela. “Insulin and Insulin Resistance.” The Clinical Biochemist. Reviews, vol. 26, no. 




Yanai, Hidekatsu, et al. “The Underlying Mechanisms for Development of Hypertension in the 
Metabolic Syndrome.” Nutrition Journal, vol. 7, BioMed Central, Apr. 2008, p. 10, 
doi:10.1186/1475-2891-7-10. 
Yates, Kathy F., et al. “Impact of Metabolic Syndrome on Cognition and Brain: A Selected 
Review of the Literature.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 
9, NIH Public Access, Sept. 2012, pp. 2060–67, doi:10.1161/ATVBAHA.112.252759. 
 
 
 
